TICKERNOMICS Sign up
Last Update: 2024-12-27 15:24:00
Amphastar Pharmaceuticals Inc. ( AMPH ) https://www.amphastar.com
38.17USD
Sector:
Healthcare
Industry:
Drug Manufacturers-Specialty & Generic
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
27.80%
-38.60%
AMPH
SPY
32.66%
AMPH
67.12%
SPY
108.59%
AMPH
98.80%
SPY
302.52%
AMPH
231.62%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
2029.88
1812.54
0.40
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
12.87
2.81
2.79
6.81
0.00
7.07
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
29.83
53.31
34.79
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
7.1904
21.05
22.47
0.78
Other Earnings and Cash Flow Stats:
Amphastar Pharmaceuticals Inc. ( AMPH ) Net Income TTM ($MM) is 157.72
Amphastar Pharmaceuticals Inc. ( AMPH ) Operating Income TTM ($MM) is 214.25
Amphastar Pharmaceuticals Inc. ( AMPH ) Owners' Earnings Annual ($MM) is 215.68
Amphastar Pharmaceuticals Inc. ( AMPH ) Current Price to Owners' Earnings ratio is 15.46
Amphastar Pharmaceuticals Inc. ( AMPH ) EBITDA TTM ($MM) is 253.04
Amphastar Pharmaceuticals Inc. ( AMPH ) EBITDA Margin is 34.79%
Capital Allocation:
Amphastar Pharmaceuticals Inc. ( AMPH ) has paid 0.00 dividends per share and bought back 2.059 million shares in the past 12 months
Amphastar Pharmaceuticals Inc. ( AMPH ) has reduced its debt by 658.188 million USD in the last 12 months
Capital Structure:
Amphastar Pharmaceuticals Inc. ( AMPH ) Interest-bearing Debt ($MM) as of last quarter is 33
Amphastar Pharmaceuticals Inc. ( AMPH ) Annual Working Capital Investments ($MM) are -42
Amphastar Pharmaceuticals Inc. ( AMPH ) Book Value ($MM) as of last quarter is 727
Amphastar Pharmaceuticals Inc. ( AMPH ) Debt/Capital as of last quarter is 4%
Other Balance Sheet Stats:
Amphastar Pharmaceuticals Inc. ( AMPH ) has 192 million in cash on hand as of last quarter
Amphastar Pharmaceuticals Inc. ( AMPH ) has 159 million of liabilities due within 12 months, and long term debt 587 as of last quarter
Amphastar Pharmaceuticals Inc. ( AMPH ) has 51 common shares outstanding as of last quarter
Amphastar Pharmaceuticals Inc. ( AMPH ) has 0 million USD of preferred stock value
Academic Scores:
Amphastar Pharmaceuticals Inc. ( AMPH ) Altman Z-Score is 3.21 as of last quarter
Amphastar Pharmaceuticals Inc. ( AMPH ) Piotroski Score is 8.00 as of last quarter
Corporate Governance:
Amphastar Pharmaceuticals Inc. ( AMPH ) largest shareholder is owning shares at 0.00 ($MM) value
Zhou Rong(an insider) Sold 8000 shares of Amphastar Pharmaceuticals Inc. ( AMPH ) for the amount of $361840.00 on 2024-12-13
22.47% of Amphastar Pharmaceuticals Inc. ( AMPH ) is held by insiders, and 74.71% is held by institutions
Amphastar Pharmaceuticals Inc. ( AMPH ) went public on 2014-06-25
Other Amphastar Pharmaceuticals Inc. ( AMPH ) financial metrics:
FCF:170.15
Unlevered Free Cash Flow:330.97
EPS:3.12
Operating Margin:29.83
Gross Profit Margin:53.31
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:22.22
Beta:0.78
Buffet's Owners Earnings:215.68
Price to Owner's Earnings:15.46
About Amphastar Pharmaceuticals Inc. ( AMPH ) :
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredient (API). It offers Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; Epinephrine injection for the emergency treatment of allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products for emergency use in hospital settings; morphine injection for use with patient controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation; and Vasopressin to increase blood pressure in adults with vasodilatory shock. Further, the company distributes recombinant human insulin APIs and porcine insulin API. It serves hospitals, care facilities, alternate care sites, clinics, and doctors' offices. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.